近红外荧光免疫治疗在卵巢癌中的研究进展

doi:10.12280/gjfckx.20220637

摘要/Abstract

摘要：

卵巢癌是致命的妇科恶性肿瘤之一，具有早期诊断困难、复发率和死亡率高等特点。尽管大多数患者在积极治疗后达到临床缓解，但超过80%的患者可能会发生耐药复发，且通常伴有淋巴结以及广泛腹腔转移。因此，亟需寻找卵巢癌治疗的新策略以延长患者的生存期及减少复发。近红外荧光免疫治疗（near-infrared photoimmunotherapy，NIR-PIT）是一种新型的分子靶向疗法，其主要结合抗体靶向肿瘤的特异性和光吸收染料暴露于近红外光后引起的毒性诱导高特异性的细胞免疫原性死亡，在肿瘤的早期诊断、治疗和耐药中发挥重要作用。综述NIR-PIT抗肿瘤作用的机制及其在卵巢癌中的研究进展。

关键词: 卵巢肿瘤, 谱学, 近红外线, 免疫疗法, 抗体, 单克隆, 光疗法, 近红外荧光免疫治疗

Abstract:

Ovarian cancer is one of the most lethal gynecological malignancies, which is characterized by difficulties in early diagnosis, high recurrence rate and mortality. Although most patients achieve clinical remission after aggressive treatment, more than 80% of patients may experience drug-resistant recurrence, usually accompanied by lymph node and extensive abdominal metastasis. There is an urgent need to find new therapeutic strategies for ovarian cancer to prolong survival and reduce recurrence. Near-infrared photoimmunotherapy (NIR-PIT) is a novel molecular targeted therapy that combines the specificity of antibody targeting tumor and light-absorbing dye exposure to near-infrared. NIR-PIT is an emerging targeted therapy for cancer, which plays an important role in the early diagnosis, treatment and drug resistance of tumors. This paper reviews the mechanism of anti-tumor effect of NIR-PIT and the current research progress of NIR-PIT in ovarian cancer.

Key words: Ovarian neoplasms, Spectroscopy, near-infrared, Immunotherapy, Antibodies, monoclonal, Phototherapy, Near-infrared photoimmunotherapy

赵调红, 逯涛峰, 陈圆圆, 路如霞, 赵源旭, 裴亚萍, 刘会玲. 近红外荧光免疫治疗在卵巢癌中的研究进展[J]. 国际妇产科学杂志, 2023, 50(2): 196-200.

ZHAO Tiao-hong, LU Tao-feng, CHEN Yuan-yuan, LU Ru-xia, ZHAO Yuan-xu, PEI Ya-ping, LIU Hui-ling. Research Progress of Near-Infrared Photoimmunotherapy in Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2023, 50(2): 196-200.

图/表 2

参考文献 25

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Morand S, Devanaboyina M, Staats H, et al. Ovarian Cancer Immunotherapy and Personalized Medicine[J]. Int J Mol Sci, 2021, 22(12):6532. doi: 10.3390/ijms22126532. doi: 10.3390/ijms22126532
[3]	Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer[J]. Acc Chem Res, 2019, 52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. doi: 10.1021/acs.accounts.9b00273
[4]	Kobayashi H, Griffiths GL, Choyke PL. Near-Infrared Photoimmunotherapy: Photoactivatable Antibody-Drug Conjugates (ADCs)[J]. Bioconjug Chem, 2020, 31(1):28-36. doi: 10.1021/acs.bioconjchem.9b00546. doi: 10.1021/acs.bioconjchem.9b00546
[5]	Sato K, Ando K, Okuyama S, et al. Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy[J]. ACS Cent Sci, 2018, 4(11):1559-1569. doi: 10.1021/acscentsci.8b00565. doi: 10.1021/acscentsci.8b00565
[6]	Ogawa M, Tomita Y, Nakamura Y, et al. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity[J]. Oncotarget, 2017, 8(6):10425-10436. doi: 10.18632/oncotarget.14425. doi: 10.18632/oncotarget.14425 pmid: 28060726
[7]	Kobayashi H, Furusawa A, Rosenberg A, et al. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity[J]. Int Immunol, 2021, 33(1):7-15. doi: 10.1093/intimm/dxaa037. doi: 10.1093/intimm/dxaa037 pmid: 32496557
[8]	van Straten D, Mashayekhi V, de Bruijn HS, et al. Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions[J]. Cancers (Basel), 2017, 9(2):19. doi: 10.3390/cancers9020019. doi: 10.3390/cancers9020019
[9]	李步洪, 陈天龙, 林立, 等. 光动力疗法基础研究与临床应用的新进展[J]. 中国激光, 2022, 49(5):3-19. doi: 10.3788/CJL202249.0507101. doi: 10.3788/CJL202249.0507101
[10]	Railkar R, Krane LS, Li QQ, et al. Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer[J]. Mol Cancer Ther, 2017, 16(10):2201-2214. doi: 10.1158/1535-7163.MCT-16-0924. doi: 10.1158/1535-7163.MCT-16-0924 pmid: 28619755
[11]	Mitsunaga M, Ogawa M, Kosaka N, et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules[J]. Nat Med, 2011, 17(12):1685-1691. doi: 10.1038/nm.2554. doi: 10.1038/nm.2554 pmid: 22057348
[12]	Paraboschi I, Turnock S, Kramer-Marek G, et al. Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications[J]. Crit Rev Oncol Hematol, 2021, 161:103325. doi: 10.1016/j.critrevonc.2021.103325. doi: 10.1016/j.critrevonc.2021.103325
[13]	Nath S, Pigula M, Khan AP, et al. Flow-induced Shear Stress Confers Resistance to Carboplatin in an Adherent Three-Dimensional Model for Ovarian Cancer: A Role for EGFR-Targeted Photoimmunotherapy Informed by Physical Stress[J]. J Clin Med, 2020, 9(4):924. doi: 10.3390/jcm9040924. doi: 10.3390/jcm9040924
[14]	Nath S, Saad MA, Pigula M, et al. Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease[J]. Cancers (Basel), 2019, 11(12):1887. doi: 10.3390/cancers11121887. doi: 10.3390/cancers11121887
[15]	Harada T, Nakamura Y, Sato K, et al. Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer[J]. Oncotarget, 2016, 7(48):79408-79416. doi: 10.18632/oncotarget.12710. doi: 10.18632/oncotarget.12710 pmid: 27765903
[16]	Sato K, Hanaoka H, Watanabe R, et al. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer[J]. Mol Cancer Ther, 2015, 14(1):141-150. doi: 10.1158/1535-7163.MCT-14-0658. doi: 10.1158/1535-7163.MCT-14-0658 pmid: 25416790
[17]	Polikarpov DM, Campbell DH, Lund ME, et al. The feasibility of Miltuximab^®-IRDye700DX-mediated photoimmunotherapy of solid tumors[J]. Photodiagnosis Photodyn Ther, 2020, 32:102064. doi: 10.1016/j.pdpdt.2020.102064. doi: 10.1016/j.pdpdt.2020.102064
[18]	Gaillard SL, Coleman RL. Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?[J]. Ann Oncol, 2019, 30(7):1025-1028. doi: 10.1093/annonc/mdz166. doi: S0923-7534(19)31250-5 pmid: 31987363
[19]	Jin J, Sivakumar I, Mironchik Y, et al. PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model[J]. Cancers(Basel), 2022, 14(3):619. doi: 10.3390/cancers14030619. doi: 10.3390/cancers14030619
[20]	Taki S, Matsuoka K, Nishinaga Y, et al. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity[J]. J Immunother Cancer, 2021, 9(11):e003036. doi: 10.1136/jitc-2021-003036. doi: 10.1136/jitc-2021-003036
[21]	Poursheikhani A, Yousefi H, Tavakoli-Bazzaz J, et al. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells[J]. Iran Biomed J, 2020, 24(6):370-378. doi: 10.29252/ibj.24.6.365. doi: 10.29252/ibj.24.6.365
[22]	Furusawa A, Choyke PL, Kobayashi H. NIR-PIT: Will it become a standard cancer treatment?[J]. Front Oncol, 2022, 12:1008162. doi: 10.3389/fonc.2022.1008162. doi: 10.3389/fonc.2022.1008162
[23]	Liang BJ, Pigula M, Baglo Y, et al. Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting[J]. J Nanobiotechnology, 2020, 18(1):1. doi: 10.1186/s12951-019-0560-5. doi: 10.1186/s12951-019-0560-5
[24]	Hongrapipat J, Kopecková P, Liu J, et al. Combination chemotherapy and photodynamic therapy with fab′ fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells[J]. Mol Pharm, 2008, 5(5):696-709. doi: 10.1021/mp800006e. doi: 10.1021/mp800006e
[25]	Rizvi I, Dinh TA, Yu W, et al. Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results[J]. Isr J Chem, 2012, 52(8/9):776-787. doi: 10.1002/ijch.201200016. doi: 10.1002/ijch.201200016